Seminars in Liver Disease

Papers
(The median citation count of Seminars in Liver Disease is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Critical Care Management of Acute-on-Chronic Liver Failure: Certainties and Unknowns99
A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD51
Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma36
Hepatic Extracellular Matrix and Its Role in the Regulation of Liver Phenotype34
Expert Practical Recommendations for Hepatocellular Carcinoma34
Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease28
Genetic and Epigenetic Basis of Drug-Induced Liver Injury26
HBV Biomarkers and Their Role in Guiding Treatment Decisions25
Emerging Targets for the Treatment of Primary Sclerosing Cholangitis23
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease23
Genetic Contributions to Biliary Atresia: A Developmental Cholangiopathy22
Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies19
Alcohol Plus Additional Risk Factors: Rodent Model of Liver Injury19
Physiomimetic In Vitro Human Models for Viral Infection in the Liver18
Mice Engrafted with Human Liver Cells18
Wilson Disease: Novel Diagnostic and Therapeutic Approaches18
Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates17
Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective16
14
Diagnosis and Management of Early Stages of ALD14
Liver Neurobiology: Regulation of Liver Functions by the Nervous System12
Role of Intestinal Barrier Disruption to Acute-on-Chronic Liver Failure12
Primary Cilia in Hepatic Biliary Hyperplasia: Implications for Liver Diseases12
11
11
To TIPS or Not to TIPS in High Risk of Variceal Rebleeding and Acute-on-Chronic Liver Failure11
Role of Complement in Liver Diseases11
Endoscopic Advances in Hepatology10
Patient-Centered Treatment of Cirrhosis10
Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future10
Hepatitis Delta Infection: A Clinical Review10
Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review10
Mesenchymal Stem Cell Transplantation in Liver Diseases10
Novel Biomarkers of AKI in Cirrhosis10
Hepatocellular Carcinoma Chemoprevention with Generic Agents10
This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol10
Management of Portal vein Thrombosis in Cirrhosis10
Erratum to: Genetic Contributions to Biliary Atresia: A Developmental Cholangiopathy9
Pediatric and Adult Liver Disease in Alpha-1 Antitrypsin Deficiency9
LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology9
Optimizing Liver Cancer Care Through BCLC Principles9
The Hepatic Porphyrias: Revealing the Complexities of a Rare Disease9
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease9
Big Data Analytics in Large Cohorts: Opportunities and Challenges for Research in Hepatology9
Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?8
Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting8
Hepatic Innervations and Nonalcoholic Fatty Liver Disease8
Advancements in MELD Score and Its Impact on Hepatology8
Nonalcoholic Fatty Liver Disease: Current Global Burden8
Extracellular Vesicles and Micro-RNAs in Liver Disease8
Research Progress on the Role and Mechanism of IL-37 in Liver Diseases8
Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD8
Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs7
Shared Mechanisms between Cardiovascular Disease and NAFLD7
Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma7
Gestational and Developmental Contributors of Pediatric MASLD6
Immune Checkpoint Inhibitor-Induced Liver Injury6
6
6
6
Alcohol-Metabolizing Enzymes, Liver Diseases and Cancer6
Influence of Sex in the Development of Liver Diseases6
Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research6
Role of Neutrophils in the Development of Steatotic Liver Disease6
The Ways to Die: Cell Death in Liver Pathophysiology6
Role of Hepatocyte Nuclear Factor 4 Alpha in Liver Cancer5
Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury5
5
5
Mastering Core Recommendations during HEPAtology ROUNDS in Patients with Advanced Chronic Liver Disease5
The Ploidy State as a Determinant of Hepatocyte Proliferation5
5
Novel Endoscopic Bariatric Therapies for the Management of Nonalcoholic Steatohepatitis5
Pathogenesis and Management of Intestinal Failure-Associated Liver Disease5
Neutrophils in Liver Diseases: Functions and Challenging Therapies5
Angiocrine Signaling in Sinusoidal Health and Disease5
MetALD: Genetic Factors and Clinical Outcomes5
Animal Models of Porphyria with Hepatic Involvement4
Practical Guide to Best Practices in Alcohol-Associated Liver Disease4
Microbial Modulation of the Gut–Liver Axis in Autoimmune Liver Diseases4
NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?4
Preface (Introduction): Metabolic Liver Disease: A New Era in Hepatology4
The Molecular Pathogenesis of Sarcopenia/Frailty in Cirrhosis4
Beyond Varices: Complications of Cirrhotic Portal Hypertension in Pediatrics4
Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease4
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets4
UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis4
0.060760021209717